Vancouver, Canada – April 15, 2025 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that multiple scientific abstracts have been accepted for presentation at major international rheumatology and diagnostics conferences throughout 2025. These presentations highlight the expanding clinical relevance of 14-3-3η (eta) autoantibodies in the diagnosis and monitoring of axial spondyloarthritis (axSpA).
As the demand for more objective, biomarker-based tools grows in autoimmune disease diagnostics, Augurex’s ongoing research continues to demonstrate how 14-3-3η autoantibodies support earlier and more accurate identification of axSpA—even in challenging clinical subgroups, such as HLA-B27 negative patients.
Upcoming Presentations:
CCR East 2025 | May 1–4, 2025 | Destin, Florida
- Abstract Title: Diagnostic Potential and Modifiability of 14-3-3η Auto-Antibodies in Axial Spondyloarthritis
Accepted as a poster presentation. Details to be shared closer to the conference date.
EULAR 2025 | June 11–14, 2025 | Barcelona, Spain
- Abstract A1600: Validation of Anti-14-3-3η (eta) Multiplex Laboratory Developed Test (LDT) for the Diagnosis of Axial Spondyloarthritis (axSpA)
Accepted as a poster presentation. Details to be shared closer to the conference date. - Abstract A1601: The 14-3-3η autoantibody assay combines with CRP and HLA-B27 to maximize the identification of patients with axial spondyloarthritis, including in HLA-B27 negative patients; A validation study.
ADLM 2025 | July 27–31, 2025 | Chicago, IL
- Abstract 8967: Development of Anti-14-3-3eta Multiplex Laboratory Developed Test (LDT) to aid in the Diagnosis of Axial Spondyloarthritis (axSpA)
Accepted as a poster presentation. Details to be shared closer to the conference date.
These presentations highlight the growing significance of 14-3-3eta autoantibodies as a first-in-class diagnostic tool for axSpA. We look forward to connecting with the global rheumatology and diagnostics communities to showcase our new data and diagnostic solutions.
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test, which detects the 14-3-3eta protein and is available as JOINTstat® in Canada, is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs expand Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which, if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn and X.
Media Contact
Nima Mazinani
(604) 674-8231
[email protected]